Scholarlink

Objective <p>To evaluate the visual outcomes, refractive accuracy, contrast sensitivity, and safety profile of the ENOVA GF3 hydrophobic monofocal intraocular lens following cataract surgery.</p> Materials and methods <p>This retrospective study included 153 eyes of 105 patients who underwent uneventful phacoemulsification with implantation of the ENOVA GF3 intraocular lens. Postoperative examinations were performed at 0–3 days, 7–10 days, 1–2 months, 4–6 months, and 11–12 months. Uncorrected and corrected distance visual acuity (UCVA and CDVA), refractive outcomes, and contrast sensitivity under photopic and mesopic conditions were evaluated. Statistical analyses were performed using the Wilcoxon signed-rank test, and a p value &lt; 0.05 was considered statistically significant.</p> Results <p>A significant improvement was observed in both UCVA and CDVA at all postoperative time points compared with preoperative values (<i>p</i> &lt; 0.001). At the 12-month follow-up, mean UCVA and CDVA reached 0.03 ± 0.06 logMAR and 0.00 ± 0.02 logMAR, respectively. The mean spherical equivalent improved significantly from preoperative values to 0.33 ± 0.21 D at 11–12 months postoperatively (<i>p</i> &lt; 0.001), indicating high refractive accuracy and stability. Contrast sensitivity measurements demonstrated a significant improvement over time under both photopic and mesopic conditions. At 11–12 months, contrast sensitivity values were significantly higher than those measured at 1–2 months across all spatial frequencies (<i>p</i> &lt; 0.05). No intraoperative complications or clinically significant postoperative adverse events, including clinically significant posterior capsular opacification requiring Nd: YAG capsulotomy, were observed during the follow-up period.</p> Conclusion <p>The ENOVA GF3 monofocal intraocular lens demonstrated excellent visual and refractive outcomes with stable long-term performance. Significant improvements in visual acuity and contrast sensitivity were observed throughout follow-up, with high refractive predictability and no clinically relevant safety concerns. These findings support the ENOVA GF3 as a reliable option for routine cataract surgery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of visual outcomes, optical quality, and patient satisfaction with a novel monofocal intraocular lens

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Cem Simsek,
  • Sabahattin Sul,
  • Ahmet Kaderli,
  • Sema Tamer Kaderli,
  • Merve Simsek,
  • Aylin Karalezli

摘要

Objective

To evaluate the visual outcomes, refractive accuracy, contrast sensitivity, and safety profile of the ENOVA GF3 hydrophobic monofocal intraocular lens following cataract surgery.

Materials and methods

This retrospective study included 153 eyes of 105 patients who underwent uneventful phacoemulsification with implantation of the ENOVA GF3 intraocular lens. Postoperative examinations were performed at 0–3 days, 7–10 days, 1–2 months, 4–6 months, and 11–12 months. Uncorrected and corrected distance visual acuity (UCVA and CDVA), refractive outcomes, and contrast sensitivity under photopic and mesopic conditions were evaluated. Statistical analyses were performed using the Wilcoxon signed-rank test, and a p value < 0.05 was considered statistically significant.

Results

A significant improvement was observed in both UCVA and CDVA at all postoperative time points compared with preoperative values (p < 0.001). At the 12-month follow-up, mean UCVA and CDVA reached 0.03 ± 0.06 logMAR and 0.00 ± 0.02 logMAR, respectively. The mean spherical equivalent improved significantly from preoperative values to 0.33 ± 0.21 D at 11–12 months postoperatively (p < 0.001), indicating high refractive accuracy and stability. Contrast sensitivity measurements demonstrated a significant improvement over time under both photopic and mesopic conditions. At 11–12 months, contrast sensitivity values were significantly higher than those measured at 1–2 months across all spatial frequencies (p < 0.05). No intraoperative complications or clinically significant postoperative adverse events, including clinically significant posterior capsular opacification requiring Nd: YAG capsulotomy, were observed during the follow-up period.

Conclusion

The ENOVA GF3 monofocal intraocular lens demonstrated excellent visual and refractive outcomes with stable long-term performance. Significant improvements in visual acuity and contrast sensitivity were observed throughout follow-up, with high refractive predictability and no clinically relevant safety concerns. These findings support the ENOVA GF3 as a reliable option for routine cataract surgery.